Atherosclerotic Risk Factor Control in Patients With Peripheral Arterial Disease

Prediction of Coronary Artery Disease in Patients With Lower Extremity Peripheral Artery Disease

“…5,6) In addition, coexistence of CAD is the most important determinant of mortality and longterm prognosis in patients with PAD 1,7,8) and patients with PAD had the same relative risk of death as those with a previous cardiovascular event. 9) However, most lower extremity PAD patients have no cardiac symptoms due to reduced daily activity and there is currently no definitive evidence which advocates for the need to perform screening tests in patients with lower extremity PAD for asymptomatic CAD. 10) Therefore, prediction of CAD could be essential for improving the survival and clinical outcome of patients with PAD.…”

Pharmacist influence on prescribing in peripheral arterial disease (PIPER)

“…This was demonstrated more recently in a larger study in the primary care setting. 15 The significance of these results should not be understated as the primary care setting may represent the ideal environment for early prophylactic intervention in this cohort of patients. Less evidence exists for the level of risk factor management in the inpatient setting where one would expect intervention to be greatest if not already achieved, particularly when admitted under specialist care.…”

“…Compliance can be an issue in this patient group 18 due to the perception that PAD is not as severe as CAD, which is evident in the under-treatment of PAD. 8,9,15,16 In addition to compliance, the time taken to gain benefit from treatment changes must be considered. Risk factor management and prescribing of antiplatelets and statins have a wealth of evidence to show that they decrease cardiovascular outcomes.…”

Quality of care among patients undergoing lower extremity revascularization

“…This pattern was also observed in a cohort of 1733 patients with isolated PAD identified by an administrative database but not confirmed by noninvasive testing. 17 More recently, a retrospective observational study demonstrated lower and less aggressive use of statins in patients with PAD versus those with coronary artery disease (CAD). 13 The use of risk factor modification in patients with symptomatic PAD who undergo LER is also low.…”